Screener
Rhythm Pharmaceuticals, Inc. RYTM Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating activities | ||
| Net loss | $(55,639) | $(49,498) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 23,099 | 12,862 |
| Depreciation and amortization | 252 | 383 |
| Non-cash interest expense | 4,577 | 5,408 |
| Non-cash accretion & amortization of short-term investments | (1,436) | (1,787) |
| Non-cash rent expense | 113 | 110 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s stock-based comp?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported stock-based comp of $23.1M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s stock-based comp changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s stock-based comp increased by 79.6% year-over-year, from $12.86M to $23.1M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s stock-based comp has grown at a 33.9% compound annual growth rate (CAGR), from $20.8M to $66.82M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude